Newport, Target, AVEO Pharmaceuticals, Astellas Pharma and Bristol-Myers Squibb highlighted as Zacks Bull and Bear of the Day

Zacks

For Immediate Release

Chicago, IL – February 03, 2014– Zacks Equity Research highlights Newport Corporation (NEWP-Free Report) as the Bull of the Day and Target (TGT-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on AVEO Pharmaceuticals, Inc. (AVEO-Free Report), Astellas Pharma, Inc. (ALPMY-Free Report) and Bristol-Myers Squibb (BMY-Free Report).
 
Here is a synopsis of all five stocks:

Bull of the Day:

Newport Corporation (NEWP-Free Report) bills itself as a "Global Leader in the Management of Light" which is a heavy way of saying they are in the business of Optics, Photonics and Lasers. A recent big beat and increase to guidance has helped make this stock a Zacks Rank #1 (Strong Buy) and it is the Bull of the Day.

One of the best things you can do to a financial portfolio is to be sure you are diversified. A sign in at the Chicago Mercantile Exchange denotes that sentiment by saying "Risk Not Thy Whole Wad" and this is an idea that is not lost on Newport.

Revenues from the products NEWP sells are spread pretty evenly over 5 large industries. They are Scientific Research, Life and Health Sciences, Microelectronics, Industrial, Defense & Security. None of those five segments accounts for more than 24% of total revenue.

The idea of diversification does not stop at it clients, it’s also prevalent in the geographies it serves. While the US accounts for the majority of sales (40%), Europe clocks in at 27% and the Pacific Rim also accounts for 26% of sales.

Bear of the Day:

Target (TGT-Free Report) credit cards being compromised might be only the tip of the iceberg for this retailer. A stream of negative earnings revisions has helped make this stock a Zacks Rank #5 (Strong Sell) and it is the Bear of the Day.

Were they hacked? Was it an inside job? Does management even really know? The company announced that 40 million accounts were compromised on December 19, 2013. That number expanded, along with the definition to 70 million and I even saw a 110 million figure.

Management moved to sack 475 souls at the company headquarters in Minneapolis and said it would not fill 700 open positions. The layoffs were the largest since 2009 when the company cut 1,100 positions from its headquarters.

Recently, I heard that the blame might have shifted to vendors ... so maybe they will keep pointing fingers until they run out of suspects.
 
 
Additional content:
 
AVEO/Astellas Terminate Breast Cancer Drug Trial
 
AVEO Pharmaceuticals, Inc. (AVEO-Free Report) and partner Astellas Pharma, Inc. (ALPMY-Free Report) announced their decision to discontinue a phase II study evaluating tivozanib in patients suffering from locally recurrent or metastatic triple negative breast cancer. The companies decided to end the phase II BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer (BC) study due to insufficient enrollment.
 
The randomized, double-blind, multi-center phase II BATON BC study was initiated in Dec 2012 to compare the efficacy of tivozanib plus Bristol-Myers Squibb’s (BMY-Free Report) Taxol (paclitaxel) with Taxol plus placebo in locally recurrent or metastatic triple negative breast cancer patients, who have not received or received one systemic therapy.
 
In its third quarter 2013 press release, AVEO had disclosed that the enrolment process for the phase II BATON BC study was slower than expected. Despite patient recruitment efforts, enrollment rates did not improve significantly.
 
This is the latest in tivozanib-related setbacks for AVEO. Last month, AVEO and Astellas had announced that data from a planned interim analysis of the phase II BATON– CRC (colorectal cancer) study on tivozanib revealed that the study was unlikely to meet the primary endpoint.
 
Prior to that, in June last year, the companies had received a complete response letter (CRL) from the U.S. Food and Drug Administration (:FDA) for tivozanib for advanced renal cell carcinoma (:RCC). The FDA had informed AVEO that the new drug application (:NDA) was not approvable in its present form. Following the CRL, AVEO decided to discontinue tivozanib development for the advanced RCC indication.
 
Our Take
 
AVEO’s shares have plunged more than 75% over the last one year. Given the disappointing news related to tivozanib, we expect the shares to continue to fall further. We expect the company to increase its focus on other pipeline candidates including AV-203 (phase I – solid tumor).
 
Get today’s Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:
 
About the Bull and Bear of the Day
 
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
 
About the Analyst Blog
 
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
 
About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
 
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.
 
About Zacks
 
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
 
Get the full Report on NEWP - FREE
Get the full Report on TGT - FREE
 Get the full Report on AVEO - FREE
Get the full Report on ALPMY - FREE
Get the full Report on BMY - FREE
 
Follow us on Twitter:  http://twitter.com/zacksresearch
 
Join us on Facebook:  http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
 
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
 
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
 
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
 
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on NEWP

Read the analyst report on TGT

Read the analyst report on AVEO

Read the analyst report on ALPMY

Read the analyst report on BMY


Zacks Investment Research

View Comments (0)